Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease

BACKGROUND: Intraputamenal glial cell line-derived neurotrophic factor (GDNF), administered every 4 weeks to patients with moderately advanced Parkinson’s disease, did not show significant clinical improvements against placebo at 40 weeks, although it significantly increased [(18)F]DOPA uptake throu...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Parkinsons Dis
Huvudupphovsmän: Whone, Alan L., Boca, Mihaela, Luz, Matthias, Woolley, Max, Mooney, Lucy, Dharia, Sonali, Broadfoot, Jack, Cronin, David, Schroers, Christian, Barua, Neil U., Longpre, Lara, Barclay, C. Lynn, Boiko, Chris, Johnson, Greg A., Fibiger, H. Christian, Harrison, Rob, Lewis, Owen, Pritchard, Gemma, Howell, Mike, Irving, Charlie, Johnson, David, Kinch, Suk, Marshall, Christopher, Lawrence, Andrew D., Blinder, Stephan, Sossi, Vesna, Stoessl, A. Jon, Skinner, Paul, Mohr, Erich, Gill, Steven S.
Materialtyp: Artigo
Språk:Inglês
Publicerad: IOS Press 2019
Ämnen:
Research Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6597995/
https://ncbi.nlm.nih.gov/pubmed/30829619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-191576
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk